Lactagard

Quick links to important sections

Lactagard

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lactagard

Lactagard is a combination anti-infective agent used to eliminate harmful bacteria, defined pharmacologically as a pairing of an antibiotic and an inhibitor. This product, manufactured by Ipca Laboratories Ltd., is a semisynthetic medicinal entity classified as a beta-Lactam antibiotic combined with a beta-Lactamase inhibitor.


Quick Facts

Property Description
Active Ingredients Cefoperazone, Sulbactam
Form Dry Powder for Injection (Parenteral)
Pharmacological Class Third-Generation Cephalosporin / beta-Lactamase Inhibitor
General Purpose Treatment of serious bacterial infections
Manufacturer/Marketer Ipca Laboratories Ltd.

What Type of Medicine is Lactagard?

Lactagard is classified as a beta-Lactam antibiotic/beta-Lactamase inhibitor combination drug. The primary antimicrobial component, Cefoperazone, is recognized as a third-generation cephalosporin. Unlike single-agent antibiotics, this formulation incorporates Sulbactam, which functions primarily as an irreversible beta-Lactamase inhibitor. This strategic dual composition distinguishes it from standalone cephalosporins. This combination is designed for enhanced efficacy against certain resistant bacterial strains, making it suitable for use in hospital settings where infections may be severe.

Composition and Pharmaceutical Form (Cefoperazone/Sulbactam)

The active components in Lactagard are Cefoperazone sodium and Sulbactam sodium, supplied as a sterile Dry Powder for Injection in a vial. This format requires reconstitution into a solution using a suitable diluent for administration. As a parenteral formulation, it is intended for direct delivery either intravenously or intramuscularly, ensuring rapid and complete systemic availability of the active ingredients. In addition to Lactagard, other brands containing the same combination include Sulperazon and Magnex Forte, although specific salt forms or excipients may vary by manufacturer.

General Purpose: Why is This Combination Necessary?

The necessity of the Cefoperazone/Sulbactam pairing stems from its ability to effectively counteract bacterial resistance, a significant clinical challenge. Sulbactam protects the Cefoperazone from being enzymatically destroyed by beta-lactamases, thereby ensuring its full potency against resistant strains. The general purpose of Lactagard is to provide a powerful, broad-spectrum anti-infective treatment that is intended to be more effective against a range of susceptible organisms than the antibiotic component would be if used alone. This makes it a standard choice for controlling persistent and serious bacterial infections.

Regulatory References

  1. Definition of Parenteral Administration (NIH)

What side effects are possible with Lactagard?

Officially Documented Adverse Reactions

The safety profile for the Cefoperazone/Sulbactam combination is based on official regulatory documentation, with adverse reactions categorized by frequency and the body system affected. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Classification Examples of Documented Reactions
Common (Reported in 1% to 10% of patients) Diarrhea, Eosinophilia, Rash, Elevated Liver Enzymes (AST/ALT), Thrombocytopenia.
Uncommon (Reported in 0.1% to 1% of patients) Headache, Nausea, Vomiting, Fever, Injection Site Reaction, Pruritus.

Serious Safety Considerations

The regulatory label identifies specific reactions that are considered serious, though their incidence may be rare. These include potentially fatal anaphylactic reactions and severe skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The combination has also been associated with hemorrhage and severe Clostridium difficile associated diarrhea (CDAD), which can occur even after treatment is finished.

Population-Specific Safety Notes

The official documentation includes specific statements for certain patient populations. For individuals with severe hepatic dysfunction, the clearance of Cefoperazone may be prolonged. For patients with renal impairment, the clearance of the Sulbactam component correlates with the creatinine clearance. Furthermore, a disulfiram-like reaction, characterized by flushing and tachycardia, has been documented when alcohol is consumed during or shortly after receiving the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Lactagard (Cefoperazone/Sulbactam) is expected to produce manifestations that are principally extensions of the adverse reactions reported with the drug. Severe neurological adverse reactions, including convulsions (seizures), are a documented concern associated with high serum concentrations of the active components.


Required Emergency Actions

Immediate emergency attention is required for any severe manifestation. Specifically, serious anaphylactic reactions require immediate emergency treatment with epinephrine and necessary supportive measures, such as the administration of oxygen and intravenous steroids. The official prescribing information mandates seeking help for such life-threatening complications.


Management and Monitoring

Treatment for an overdose is defined as symptomatic and supportive. Regulatory documents confirm that both active components, Cefoperazone and Sulbactam, are removable from the body's circulation by hemodialysis, a procedure that may be utilized to enhance elimination of the drug. No specific antidote for this combination agent is documented in the official labeling.

Patients with concurrent hepatic dysfunction and renal impairment are at increased risk for drug accumulation, which necessitates the close monitoring of serum concentrations to manage potential toxicity.

Therapeutic Uses of Lactagard

What Lactagard Treats: Main Uses and Benefits

Lactagard (Cefoperazone/Sulbactam) is a combination anti-infective agent commonly used in the symptomatic management of serious bacterial infections, particularly those that are severe, deep-seated, or caused by organisms resistant to common treatments. This combination is typically indicated for a wide range of susceptible infections, including Respiratory Tract Infections, Intra-abdominal Infections, Septicemia, Meningitis, Skin and Soft Tissue Infections, Bone and Joint Infections, and Gynecological Infections. The core therapeutic benefit is its role in managing symptoms that lead to acute or disruptive episodes in high-risk scenarios.

Treating Severe and Multidrug-Resistant Infections

This medication is considered relevant for managing conditions that involve heightened physiological activity like septicemia (bloodstream infections) and severe hospital-acquired pneumonia. It is specifically reserved for use when there is suspicion or confirmation of pathogens with multidrug resistance, such as certain ESBL-producing organisms. This intervention is applied across domains where additional symptomatic support is needed.

Easing Acute Systemic and Localized Symptoms

Lactagard helps address symptom clusters that may become intense or disruptive, including persistent high fever and chills, which are symptoms related to systemic imbalance. When applied in situations with heightened symptoms, it provides supportive symptom relief from localized manifestations like intense pain in soft tissue infections or severe, productive cough and sputum associated with severe pneumonia.


Quick Fact: Relief for Systemic Imbalance

Feature Description
Primary Focus Conditions marked by increased physiological stress and systemic or localized discomfort.
Symptom Type Symptoms related to systemic imbalance, such as persistent fever, and intense localized pain and inflammation.
General Benefit Supports the patient during difficult acute episodes by easing distress and helping maintain functional stability.
Clinical Scenario Used in clinical settings that involve acute or unstable symptom patterns, such as in Intensive Care Units.

Regulatory References

  1. Pfizer Sulbactam/Cefoperazone Labeling

Eligibility and Restrictions for Use

Absolute Contraindications

Lactagard (Cefoperazone/Sulbactam) is absolutely contraindicated for individuals with a known allergy or history of hypersensitivity to cefoperazone, sulbactam, penicillins, or any other cephalosporin-class antibiotic.

Population Eligibility Restrictions

Use is established for the general adult and pediatric populations. However, regulatory documents define specific conditions that restrict or limit eligibility:

  • Organ Function: Patients with a marked decrease in renal function (creatinine clearance <30 mL/min) or severe hepatic dysfunction require restricted use and possible dosage adjustments. Close monitoring is required if both conditions are present.
  • Pregnancy and Lactation: Use during pregnancy is restricted, recommended only if clearly needed (Category B legacy). Caution should be exercised when administering the medicine to nursing mothers.
  • Infants: Use in premature infants or neonates has not been extensively studied. A specific 12 hour dosing interval applies to neonates in the first week of life.
  • Behavioral Prohibition: The ingestion of alcohol (including beverages or alcohol-containing products) is strictly prohibited during therapy and for up to five days after the final administration.
  • Comorbidities: Caution and monitoring are required for patients with a history of malabsorption, poor nutrition, or existing bleeding problems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction information for Lactagard (Cefoperazone/Sulbactam) based on government regulatory labeling, focusing strictly on required monitoring and constraints.


Documented Medicinal Product Interactions

Product/Category Officially Described Constraint
Oral Anticoagulants Co-administration carries an officially noted risk of increased bleeding or coagulopathy.
Aminoglycosides Requires monitoring of renal function during concurrent therapy; must not be mixed directly in solution due to physical incompatibility.

Other Documented Interactions and Constraints

Substance/Condition Official Regulatory Note
Alcohol Ingestion during treatment and up to five days following administration is associated with a disulfiram-like reaction (e.g., flushing, tachycardia).
Lactated Ringer's Incompatible for initial reconstitution of the dry powder.

Population-Specific Interaction Notes

The interaction profile includes cautions regarding pre-existing conditions that may alter drug clearance or risk:

  • Hepatic Dysfunction: The pharmacokinetics of Cefoperazone correlate with the degree of liver impairment, which may affect the overall interaction profile.
  • Renal Dysfunction: The clearance of the Sulbactam component is correlated with Creatinine Clearance, necessitating specific adjustment considerations in marked renal impairment.
  • Poor Diet / Malabsorption: Patients with these conditions are noted to be at an increased risk of developing Vitamin K deficiency, which enhances the drug's coagulopathy risk.

Mechanism of Action

How Lactagard Works

The mechanism of Lactagard is a synergistic two-part action that involves the core bactericidal mechanism and the protection of the antibiotic component from bacterial enzyme activity.

Inhibition of Bacterial Cell Wall Construction

The Cefoperazone component functions as an irreversible inhibitor of essential microbial enzymes called Penicillin-binding proteins (PBPs), specifically the D,D-transpeptidases. By binding covalently to these enzymes, Cefoperazone blocks the final step of peptidoglycan cross-linking, thereby preventing the formation of a rigid bacterial cell wall. This structural destabilization activates bacterial autolytic enzymes, which leads inevitably to cell lysis of susceptible microbial populations.

Enzymatic Protection Against Resistance

The co-formulated component, Sulbactam, operates by targeting bacterial beta-Lactamase enzymes, which function as a defense mechanism. Sulbactam functions as a suicide substrate, irreversibly binding to the enzyme's active site to form a stable complex that permanently inactivates the beta-Lactamase. This protective action maintains Cefoperazone's concentration at the PBP target, which restores the ability of Cefoperazone's cell wall inhibition mechanism to proceed against strains producing beta-Lactamase.

Dosage and Administration Information

How to Use Lactagard: Administration Guidelines

The administration of Lactagard (Cefoperazone/Sulbactam) follows established prescribing information, focusing on the correct parenteral method and established dosing protocols. This medication is supplied as a Dry Powder for Injection and requires a healthcare professional to reconstitute it using a compatible diluent, such as Sterile Water for Injection or 0.9% Sodium Chloride, before it can be used.

Administration Scope and Timing

The approved route of administration is parenteral, involving either an Intravenous (IV) intermittent infusion or an Intramuscular (IM) injection. When administered intravenously, the solution must be infused over a period of 15 to 60 minutes. The standard dosing schedule for adults requires the total daily dose to be administered in equally divided doses typically given every 12 hours.

Standard Dosing and Adjustments

Administration Detail Guideline
Adult Daily Dose Range 2 g to 4 g of the total combination (Cefoperazone:Sulbactam).
Maximum Dose Up to 8 g to 12 g of the total combination for severe infections.
Pediatric Dose 40 to 80 mg/kg/day of the combination in divided doses.

Dose adjustments are a part of the usage protocol for certain populations. For patients with significant renal impairment (creatinine clearance < 30 mL/min), the maximum daily dose of the Sulbactam component is restricted. Similarly, the Cefoperazone component should not exceed 2 g/day without therapeutic monitoring in cases of severe hepatic dysfunction. The typical duration of treatment is generally 7 to 14 days, continuing until clinical improvement is maintained for 48 hours.

Recent Clinical Evidence

Lactagard (Cefoperazone/Sulbactam) has been extensively studied in research examining its evidence for use in various severe infections. The core evidence for its role in severe abdominal and pelvic infections is based on Randomized Controlled Trials (RCTs) and systematic reviews of this trial data. These studies primarily measure clinical outcome rates and rates of bacterial clearance in adult and adolescent patients, often tracking results for up to 30 days. Measurements of clinical outcomes from these trials are reported alongside established treatments used as controls.

Research has also explored evidence for the combination in infections caused by multidrug-resistant (MDR) bacteria, such as Acinetobacter baumannii. The evidence here relies more heavily on systematic reviews of retrospective and observational studies, which track clinical outcomes and survival measurements in critically ill adult patients. Findings indicate patterns related to clinical outcomes in these high-risk groups, though certainty remains low compared to large-scale RCTs, and research is still needed. The evidence base for general susceptible infections is rooted in older, foundational comparative trials.

For special populations, research has established parameters for use in pediatric cohorts, but data for groups with multiple complex comorbidities are limited. Overall, research typically focuses on intermediate-term outcomes, with primary efficacy assessed up to 30 days. Long-term effects and patient outcomes beyond this period are not fully established, representing a key research gap. The noted need for more prospective Randomized Controlled Trials to further evaluate evidence in the face of multidrug resistance is a significant limitation in the current research base.

Key Studies & References

  1. Sulbactam Sodium/Cefoperazone Sodium Trade Name: SULPERAZON CDS (Core Data Sheet)

Frequently Asked Questions (FAQ)

Common questions about Lactagard (FAQ)


Q: Do I need a prescription to get Lactagard?

Lactagard is classified as a prescription-only medicine in official documents. Because it is an anti-infective agent provided as an injection, its use and administration are typically restricted to a healthcare setting and is designated to be administered by or under the order of a licensed health care professional.


Q: Is it common to feel tired when taking Lactagard?

General tiredness and weakness are noted as possible but rare side effects in the official product information. This means they are not among the most commonly reported effects, but they are recognized as reactions that may occur.


Q: Does Lactagard interact with vitamins or supplements?

Regulatory labels do not specifically list interactions with common vitamins or supplements. However, official information indicates a risk for patients with existing poor diet or malabsorption, which can lead to a deficiency of Vitamin K. This deficiency is noted because it may contribute to the drug's risk of bleeding.


Q: What if I take Lactagard and another common over-the-counter pain reliever?

Official drug interaction information notes that combining Lactagard with certain nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of bleeding or coagulopathy. The use of other pain relievers is an item for professional evaluation to ensure there is no increased risk of adverse events.


Q: What is the purpose of the inactive ingredients in Lactagard?

The active components are Cefoperazone sodium and Sulbactam sodium. While patient summaries do not fully detail inactive ingredients (excipients), their primary purpose is to ensure the medicine remains stable, maintains its integrity, and can be properly reconstituted from a dry powder into a usable solution.


Q: How is Lactagard different from a probiotic?

Lactagard is an antibiotic combination designed to eliminate harmful bacteria, or inhibit their growth. A probiotic, by contrast, is a preparation of live microorganisms intended to support the body's natural flora, meaning these two preparations have fundamentally different actions on the body's microbial populations.


Q: Is there a generic version of Lactagard available?

Lactagard is a brand name for the combination of Cefoperazone and Sulbactam. Official documents list other brands containing the same combination, such as SULPERAZON and MAGNEX FORTE, which are often considered therapeutic equivalents.


Q: Is it okay to stop taking Lactagard suddenly?

Official information describes the medication as being intended for use exactly as directed. Skipping doses or not completing the full course of therapy may decrease effectiveness and increase the risk of developing drug-resistant bacteria.


Q: What should I do if I notice a rash after starting Lactagard?

A rash is a documented possible adverse reaction. Official regulatory information advises that severe allergic reactions, including serious rashes, can be potentially life-threatening and are serious adverse events described in official documents as needing immediate medical attention.


Q: Can Lactagard be split in half if needed?

No. Lactagard is supplied as a dry powder that must be reconstituted into a solution. It is administered directly by injection into a vein (intravenously) or muscle (intramuscularly); it is not an oral tablet or capsule that can be physically split.


Q: Has Lactagard been studied in older adults?

Official product information notes that appropriate studies have not demonstrated problems specific to the geriatric population that would limit its usefulness. However, older patients are generally more likely to have age-related liver or kidney conditions, which may present circumstances where professional dose adjustments are considered.


Q: Can Lactagard affect my sleep?

The regulatory label does not specifically mention insomnia or sleep disturbance as a common or uncommon side effect. However, documented adverse reactions such as fever and headache are possible, and these could indirectly affect the quality of sleep.


Q: What are the signs that Lactagard is starting to wear off?

Dosing is typically administered every 12 hours. This time frame is based on the components' half-life (how long it takes for half of the drug to be cleared), which is necessary to maintain continuous therapeutic drug concentrations in the body to control the infection.


Q: Does Lactagard contain any common allergens like gluten or lactose?

The active ingredients are Cefoperazone sodium and Sulbactam sodium. While the regulatory documents may not explicitly state the absence of every excipient, the final composition is an item for confirmation with a healthcare professional or pharmacist, particularly if there is a severe, known allergy.


Q: Is Lactagard considered a controlled substance?

No. Lactagard (Cefoperazone/Sulbactam) is classified as an anti-infective medicine. It is not currently classified as a controlled substance by major regulatory authorities like the U.S. Drug Enforcement Administration.


Q: What is the legal classification of Lactagard in terms of safety?

The medicine is legally classified as 'Rx Only' (Prescription Only). This classification indicates that the medicine is designated for administration only by or on the order of a licensed health care professional due to the nature of its use and administration.


Q: Are there different strengths or versions of Lactagard?

Yes, official documents indicate that the product is supplied in different ratios of Sulbactam to Cefoperazone. This allows for flexibility in professional dosing based on the severity and type of infection being treated.

How should Lactagard be stored and disposed of?

How to Store and Dispose of Lactagard (Ceftriaxone and Sulbactam)

Official regulatory information defines the specific conditions required for the storage and disposal of Lactagard injection.

Storage and Stability Requirement Official Regulatory Mandate
Unopened Product Storage Store the medicine below 30 C in a dry place. Protect from light.
Shelf Life Unopened product shelf life is 24 to 36 months.
In-Use Stability The reconstituted solution should preferably be used immediately. Any unused solution must be discarded within 24 hours.
Handling Constraint Do not mix the product with calcium-containing diluents (e.g., Ringer's solution) during preparation.
Child Safety Keep the medicine out of the reach of children.
Disposal Any unused solution must not be stored and should be discarded properly according to official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lactagard found in:

A-Z Index: